Normosang (Human Hemin)

Human Hemin supplies external heme, which feeds back to inhibit aminolevulinic acid synthase, the first enzyme in the heme biosynthetic pathway. This feedback reduces the buildup of upstream porphyrin intermediates that cause the clinical manifestations of acute porphyria attacks.

The dosage of Normosang is determined by the prescribing physician based on the severity of the porphyria attack, patient weight, and clinical response. The prescriber will calculate the appropriate amount and infusion rate for each individual case.

Safety data for Normosang in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To order Normosang, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Normosang is a heme preparation that directly replaces deficient heme, whereas alternative therapies may focus on symptom control or use different mechanisms such as enzyme inhibition. Compared with oral agents, intravenous Human Hemin provides rapid biochemical correction during acute attacks, making it the preferred option for severe episodes.

Normosang should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The lyophilized powder should be reconstituted with the supplied diluent immediately before intravenous infusion and used according to aseptic technique.

Normosang is supplied as a lyophilized powder for intravenous infusion. After reconstitution with the appropriate diluent, the solution is administered through a controlled IV infusion set, typically over a period defined by the prescriber, under close clinical monitoring.

The most serious risks include severe hypotension, hemolysis (especially in patients with G6PD deficiency), and anaphylactic reactions. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after the infusion.

Normosang is contraindicated in patients with known hypersensitivity to Human Hemin or any component of the formulation. It should also be avoided in individuals with severe G6PD deficiency due to the risk of hemolysis, and in patients where alternative, safer therapies are available.